{"id":"W4407007830","doi":"10.1182/bloodadvances.2024013656","title":"Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel","year":2025,"lang":"en","type":"review","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; MorphoSys; Seagen; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; bluebird bio; Medac; Jazz Pharmaceuticals; BeiGene; HistoGenetics; Atara Biotherapeutics; CareDx; Actinium Pharmaceuticals; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; CSL Behring; Bristol-Myers Squibb; AstraZeneca; Gateway for Cancer Research; Swedish Orphan Biovitrum; Omeros Corporation; Vertex Pharmaceuticals; Alexion Pharmaceuticals; Mallinckrodt Pharmaceuticals; Astellas Pharma US; Amgen; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Hazard ratio; Odds ratio; Internal medicine; Refractory (planetary science); Leukapheresis; Surgery; Gastroenterology; Confidence interval","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003487063,0.0005626563,0.003446017,0.001115365,0.0002307347,0.001495278,0.000663604,0.001054517,0.002044663],"category_scores_gemma":[0.007738463,0.0004003589,0.01195128,0.002001541,0.0002802727,0.0008376349,0.0004231546,0.001542877,0.0001804599],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009482196,"about_ca_system_score_gemma":0.0008683463,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002424591,"about_ca_topic_score_gemma":0.004411116,"domain_scores_codex":[0.9971792,0.001214956,0.0006995796,0.0004682796,0.0003169185,0.0001211829],"domain_scores_gemma":[0.9947319,0.003223844,0.001486355,0.0001113034,0.0002978252,0.0001487568],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","study_design_scores_codex":[0.06036297,0.0003573357,0.08619767,0.1794326,0.572059,0.0002571736,0.0002238292,0.002232726,0.001488061,0.000525289,0.003010657,0.09385268],"study_design_scores_gemma":[0.01183788,0.004744621,0.1024808,0.01877381,0.8481037,0.0004127565,0.0002120068,0.001419281,0.000811071,0.001192071,0.009911426,0.0001006453],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0745497,0.9212753,0.0004284807,0.0006990645,0.0002328894,0.0001282543,0.001529484,0.0000161847,0.001140525],"genre_scores_gemma":[0.8522301,0.1433176,0.0005718249,0.001504224,0.0003067979,0.0002000678,0.001391379,0.0000215231,0.0004566041],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003487063,"threshold_uncertainty_score":0.01844156,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01537286737108856,"score_gpt":0.3482179956828738,"score_spread":0.3328451283117853,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}